Core Viewpoint - Changfeng Pharmaceutical's application for the marketing authorization of Budesonide nasal spray has been accepted by the National Medical Products Administration of China, indicating the company's commitment to expanding its product pipeline in the field of allergic rhinitis and respiratory treatments [1] Product Pipeline - The company has established a comprehensive product matrix covering various indications and full-course management of respiratory and rhinitis conditions, leveraging its nasal drug delivery technology platform [1] - Existing products in the company's portfolio include: - Azelastine/Fluticasone nasal spray (Shu Fei Min®): The first antihistamine-steroid combination nasal spray in China, included in the National Medical Insurance Drug List in 2023 [1] - Mometasone nasal spray: A first-line medication for allergic rhinitis in adults and children aged 3 and above [1] - Budesonide nasal spray: Targeted for patients aged 6 and above, addressing seasonal acute episodes, perennial maintenance treatment, and nasal polyps [1] - Olopatadine/Mometasone nasal spray: Designed for adolescents aged 12 and above and adults with moderate to severe allergic rhinitis symptoms [1] Strategic Commitment - The acceptance of the Budesonide nasal spray application further enriches the company's product pipeline in the allergic rhinitis sector, demonstrating its determination and capability to deepen its presence in the respiratory inhalation treatment field [1] - The company will actively communicate with the NMPA and advance subsequent review procedures in accordance with regulatory requirements [1]